GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Inventage Lab Inc (XKRX:389470) » Definitions » Debt-to-Revenue

Inventage Lab (XKRX:389470) Debt-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inventage Lab Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Inventage Lab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Inventage Lab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Inventage Lab's annualized Revenue for the quarter that ended in Mar. 2024 was ₩387.7 Mil. Inventage Lab's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.


Inventage Lab Debt-to-Revenue Historical Data

The historical data trend for Inventage Lab's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventage Lab Debt-to-Revenue Chart

Inventage Lab Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A 9.09 2.13 0.75 16.28

Inventage Lab Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.66 17.30 40.18 5.94 -

Competitive Comparison of Inventage Lab's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Inventage Lab's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventage Lab's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Inventage Lab's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Inventage Lab's Debt-to-Revenue falls into.



Inventage Lab Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Inventage Lab's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4478.131 + 6236.167) / 658.152
=16.28

Inventage Lab's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 387.712
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Inventage Lab Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Inventage Lab's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Inventage Lab (XKRX:389470) Business Description

Traded in Other Exchanges
N/A
Address
24, Dunchon-daero 388 beon-gil, 612, Woolim Lions Valley 3, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR, 13403
Inventage Lab Inc operates medical technology development businesses. It engages in the development of an innovative Drug Delivery System (DDS). It has developed Laminar FluiDigm, a microfluidics-based novel platform technology that builds the foundation for IVL- DrugFluidic and IVL-GeneFluidic, which are specific platform technologies used for developing and manufacturing long-acting injectables and gene-delivery therapeutics.

Inventage Lab (XKRX:389470) Headlines

No Headlines